celecoxib oral / Generic mfg. - LARVOL DELTA

Repurposing disulfiram for ALDH-positive NSCLC: Network-based inhibition of EGFR, COX-2, and MAPK1. (PubMed, J Mol Graph Model) - "These targets were found to bind DSF with very high affinity (7.45 -6.15 -6.65 kcal/mol, respectively) in comparison to reference inhibitors (Erlotinib, Celecoxib, Sorafenib). The article presents mechanistic support to the multi-target effect of DSF in ALDH + NSCLC through inhibition of EGFR, COX-2, and MAPK1, potent agents of stemness and resistance to drugs. It is believed that the reuse of DSF would be effective in treating NSCLC therapeutic resistance and promote its use in practice."

Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • MAPK1 • PACERR • PTGS2

Self-Assembled Carrier-Free Nanomedicines Potentiate Chemo-Photothermal Immunotherapy by Overcoming Prostaglandin E2-Mediated Immunosuppression. (PubMed, Small) - "Herein, this work developed an excipient-free nanomedicine (IPC NPs) via non-covalent self-assembly, integrating indocyanine green and paclitaxel (dual ICD inducers) with celecoxib (COX-2/PGE2 inhibitor) for combined chemo-photothermal therapy with anti-inflammatory effects. These immunomodulatory effects substantially ameliorated the immunosuppressive tumor microenvironment, leading to significant inhibition of primary tumor growth and metastasis. Collectively, this work presents a novel carrier-free nanotherapeutic strategy that synergistically combines chemo-photothermal-inflammatory suppression therapy, offering a promising approach for TNBC."

Journal • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical Trial. (PubMed, JAMA Oncol) - P3 | "Observational studies have associated use of aspirin and selective cyclooxygenase inhibitors with decreased recurrence and improved survival in patients with colon cancer...This was a post hoc analysis of the phase 3 Cancer and Leukemia Group B (now Alliance)/Southwest Oncology Group 80702 randomized clinical trial (2010-2015) assessing adjuvant celecoxib vs placebo and 3 vs 6 months of adjuvant 5-fluorouracil, leucovorin, and oxaliplatin for stage III colon cancer...The findings of this post hoc analysis suggest that ctDNA status has the potential to inform clinical decision-making among patients with stage III colon cancer who should consider adjuvant celecoxib in addition to conventional chemotherapy. ClinicalTrials.gov Identifier: NCT01150045."

Circulating tumor DNA • Clinical • Journal • P3 data • Retrospective data • Colon Cancer • Colorectal Cancer • Hematological Malignancies • Leukemia • Microsatellite Instability • Oncology • Solid Tumor • MSI • PIK3CA

Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. (PubMed, Nat Med) - P2 | "In the exploratory NICHE study (ClinicalTrials.gov: NCT03026140), patients with dMMR or pMMR tumors received a single dose of ipilimumab and two doses of nivolumab before surgery, the pMMR group with or without celecoxib. CD8PD-1 T cell infiltration was predictive of response in pMMR tumors. These data indicate that neoadjuvant immunotherapy may have the potential to become the standard of care for a defined group of colon cancer patients when validated in larger studies with at least 3 years of disease-free survival data."

Clinical • Journal • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Neoadjuvant nivolumab, ipilimumab, and celecoxib in MMR-proficient and MMR-deficient colon cancers: Final clinical analysis of the NICHE study. (ASCO 2022) - P2 | "These data confirm our previously published results of the NICHE study, with responses to neoadjuvant nivolumab plus ipilimumab in 30% of pMMR and 100% of dMMR CC in the completed original cohorts. Validation of the dMMR responses in a large group of dMMR patients is ongoing and has the potential to change current practice."

Clinical • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Immunology • Myositis • Oncology • Solid Tumor

The addition of celecoxib enhances the therapeutic benefit of cabozantinib and anti-PD1 in hepatocellular carcinoma. (PubMed, Biomed Pharmacother) - "In the phase III COSMIC-312 trial, cabozantinib plus atezolizumab prolonged progression-free survival but did not improve overall survival, indicating the presence of tumor-intrinsic resistance mechanisms...This combination provides a strong mechanistic rationale for clinical translation and may inform future strategies to improve the durability of immune-based treatments for advanced HCC. This strategy may also guide future clinical trial designs and support the development of more effective, personalized therapies for patients with advanced HCC."

Journal • Hepatocellular Cancer • Oncology • Solid Tumor

RECON: Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer (clinicaltrials.gov) - P2 | N=39 | Recruiting | Sponsor: Emory University | Not yet recruiting ➔ Recruiting

Enrollment open • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

Evaluating adverse events reported for non-steroidal anti-inflammatory drugs in osteoarthritis: a real-world pharmacovigilance study. (PubMed, Inflammopharmacology) - "This study complementing evidence from clinical trials and epidemiological research, by detecting potential adverse reaction signals not fully captured or reflected in approved product information, thus providing a pharmacovigilance perspective grounded in real-world data."

Adverse events • Journal • Real-world evidence • Cardiovascular • CNS Disorders • Depression • Dermatology • Dyspepsia • Gastrointestinal Disorder • Hematological Disorders • Immunology • Inflammation • Ischemic stroke • Musculoskeletal Diseases • Musculoskeletal Pain • Osteoarthritis • Pain • Peptic Ulcer • Psychiatry • Respiratory Diseases • Rheumatology • Vascular Neurology

Perioperative propranolol and celecoxib (ProCel) in stage III melanoma (ANZCTR) - P2 | N=40 | Withdrawn | Sponsor: Sydney Local Health District | Not yet recruiting ➔ Withdrawn

IO biomarker • Trial withdrawal • Cutaneous Melanoma • Melanoma • Oncology • Solid Tumor • B2M • FCGR3A • HAVCR2 • MITF • PD-L1

Ly6G+ granulocytes-derived IL-17 limits protective host responses and promotes tuberculosis pathogenesis. (PubMed, Elife) - "Neutralizing IL-17 (anti-IL17mAb) and COX2 inhibition by celecoxib reverse Ly6G+Gra infiltration, associated pathology, and death in ifng-/- mice...Furthermore, in pulmonary TB patients, high neutrophil count and IL-17 correlated with adverse treatment outcomes. Together, our results suggest that IL-17 and PGE2 are the negative correlates of protection, and we propose targeting the pro-pathogenic IL-17-COX2-Ly6G+Gra axis for TB prevention and therapy."

Journal • Infectious Disease • Inflammation • Pulmonary Disease • Respiratory Diseases • Tuberculosis • IFNG • IL17A

Multifunctional Se-Cu bimetallic nanoparticles from marine Bacillus licheniformis: targeting oxidative stress, inflammation, and microbial biofilms. (PubMed, RSC Adv) - "Anti-inflammatory assessment demonstrated COX-1 inhibition up to 97.3% (IC50 = 7.05 µg mL-1) and COX-2 inhibition reaching 95.3% (IC50 = 12.11 µg mL-1) vs. celecoxib's IC50 values of 5.93 and 4.51 µg mL-1, respectively...albicans 96.09%, B. subtilis 93.76%, E. coli 91.59%), though S. aureus required higher concentrations (84.33% at 75% MBC). These results demonstrated that marine bacterial metabolites produce biocompatible Se-Cu BMNPs with potent antioxidant, anti-inflammatory, antimicrobial, and antibiofilm properties suitable for biomedical applications."

Journal • Infectious Disease • Inflammation

Cellulose Nanocrystal-Based Sulfatase-Responsive Hydrogel for Sustained Celecoxib Release in Ulcerative Colitis Therapy. (PubMed, Biomater Res) - "In a dextran sulfate sodium-induced UC mouse model, the celecoxib-loaded PDADMAC-CNC hydrogel effectively alleviated colonic inflammation, preserved colon structure, and reduced pro-inflammatory cytokine levels more markedly than free drug administration. This finding highlights the potential of sulfatase-responsive PDADMAC-CNC hydrogels as a targeted, safe, and effective approach for treating inflammatory bowel diseases, such as UC."

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

Novel thiadiazole derivatives: synthesis, in silico, in vitro and in vivo evaluation of analgesic and anti-inflammatory activities. (PubMed, Bioorg Chem) - "Based on docking scores comparable to celecoxib, three compounds (4d, 4e, 4 f) were selected for in vivo pharmacological testing...Molecular docking analyses further confirmed stable COX-2 binding interactions, supporting their selective inhibitory potential. Collectively, these findings suggest that the newly synthesized thiadiazole derivatives hold potential as analgesic and anti-inflammatory drug candidates and needs to be evaluated through comprehensive preclinical and clinical studies in future."

Journal • Preclinical • Inflammation • Pain

Friction-adaptive hydrogel coating for mechanical-immune synergy in ligament-to-bone integration. (PubMed, Biomaterials) - "Pluronic F127 diacrylate (PF127-DA) introduces a thermoresponsive structure allowing the hydrogel to transition from injectable fluid at 4 °C to a stable gel at 37 °C, enabling localized and phase-specific release of celecoxib (CXB)...In vivo studies reveal a dose-dependent regulatory effect of CXB, where low-dose delivery promotes M2 macrophage polarization, H-type vessel formation, and bone bridging, while high doses impair immune homeostasis and osteointegration. This work establishes a robust, biologically responsive interface strategy, advancing the design of innovative coatings for enhanced outcomes in artificial ligament integration."

Journal • Fatigue • Fibrosis • Immunology • Inflammation

A comparative study of some NSAIDs with natural products: integrating in vitro anticancer efficacy, in vivo antiulcerative effect, histochemistry, and in silico analysis. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "Herein, dose- and time-dependent in vitro anticancer activity studies of anti-inflammatory drugs, including celecoxib (C), indomethacin (I), and meloxicam (M), in combination with natural products (taxifolin (T), quercetin (Q), and rutin (R)) and doxorubicin (Dox), were carried out in MDA-MB-231, BT-20, MCF-7, and HT-29 human cancer cell lines. The obtained results highlight that drug C and T may be potential inhibitor candidates as SphK1 inhibitors for targeted cancer therapy. Overall, the combination of drug C with T has shown promising results, anticancer effects in breast and colon cancer cells and antiulcerative effects in rats."

Journal • Preclinical • Breast Cancer • Colon Cancer • Colorectal Cancer • Oncology • Solid Tumor • SPHK1

Inflammation-driven IL-1β–NOTCH signalling promotes pre-neoplastic transitions in biliary epithelium (LCS 2026) - "Although COX2 inhibition (aspirin, celecoxib) failed to suppress tumour initiation, inflammation cessation or blockade of NOTCH signalling—via Rbpjκ deletion or the γ-secretase inhibitor Crenigacestat—prevented BilIN formation. Conclusion Inflammation permits tumour initiation by re-wiring IL-1β–NOTCH signalling in mutant biliary epithelium, establishing an oncofoetal state that drives early neoplasia. Targeting developmental reactivation through Notch inhibition offers a rational prophylactic strategy for patients with chronic biliary inflammation at high risk of cholangiocarcinoma."

Biliary Cancer • Cholangiocarcinoma • Gastrointestinal Cancer • Solid Tumor • CCL2 • IL1B • MMP7 • PTEN • TP53

Toxicological Effects of Thymoquinone in Combination With Celecoxib and Irinotecan on DNA Damage, Oxidative Stress, G2/M Arrest, Apoptosis, and Inflammatory Response in SW620 Cells. (PubMed, J Biochem Mol Toxicol) - "In conclusion, this study shows that the combination of TQ with IR, Clx, or both exerts significant effects on SW620 colon cancer cells, such that by enhancing DNA damage, TQ may induce G2/M cell cycle arrest and apoptosis, while reducing inflammatory responses, oxidative stress, and G0/G1 cell cycle arrest. These in vitro findings indicate that TQ may enhance the chemotherapeutic effects of IR and act as a potential adjuvant therapy; however, further in vivo studies are required to verify its suggested effects."

IO biomarker • Journal • Colon Cancer • Colorectal Cancer • Inflammation • Oncology • Solid Tumor • BAX • BCL2 • BCL2L1 • CDKN1A

Anti-Inflammatory Treatment and Active Physical Therapy Have Differing Effects on Functional, Mechanical, and Histological Properties in a Rat Model of Post-Traumatic Elbow Contracture. (PubMed, J Biomech Eng) - "Animals received either anti-inflammatory drug (celecoxib or CEL) treatment, active physical therapy (wheel activity or WA), or both (CELWA)...Physical therapy resulted in the most improvement in functional parameters, but active joint use in combination with anti-inflammatory drug treatment showed the most improvement in joint mechanics and histological properties. PTJC involves multiple tissues and cell types, and thus a multi-treatment approach will likely be needed to address all underlying causes: biological modulation of the inflammatory response combined with physical disruption of fibrotic tissue may show more efficacy than either treatment alone."

Journal • Preclinical • Fibrosis • Immunology • Inflammation

Celecoxib in combination with foot and ankle orthoses for the treatment of acute ankle injuries: A study on the correlation between anti-inflammatory and analgesic mechanisms and functional recovery. (PubMed, Pak J Pharm Sci) - "The synergistic treatment enhances efficacy through anti-inflammatory and biomechanical stabilization effects, with good safety profile and patients with left-sided injuries benefit more."

Clinical • Journal • Inflammation • Orthopedics • Pain • CRP • IL6

Comparative analysis of combined oral contraceptives and non-steroidal anti-inflammatory drugs (NSAIDS) in treating dysmenorrhea: A multi-center study. (PubMed, Pak J Pharm Sci) - "Both have some efficacy in the treatment of dysmenorrhoea and compound oral contraceptives were found to be more effective, which is worth promoting their use in the clinic."

Clinical • Journal • Gynecology • Oncology • Pain • Women's Health

Clinical study of the ability of celecoxib combined with olanzapine and paroxetine hydrochloride to improve depression,anxiety and analgesic effects in patients after hemorrhoidal surgery (ChiCTR) - P=N/A | N=60 | Completed | Sponsor: Affiliated Hospital of Jining Medical University; Affiliated Hospital of Jining Medical University

New trial • CNS Disorders • Depression • Gastroenterology • Pain • Psychiatry

A Single-Center, Randomized Controlled Clinical Study of Injectable Hyaluronidase Combined with Celecoxib Capsules for the Treatment of Osteoarthritis (ChiCTR) - P=N/A | N=50 | Not yet recruiting | Sponsor: West China Hospital, Sichuan University; West China Hospital, Sichuan University

New trial • Immunology • Osteoarthritis • Pain • Rheumatology

Computational strategies for unraveling insights from known inhibitors for further lead optimization: A case study on Celecoxib analogues. (PubMed, Sci Rep) - "Further, the Structure-Activity Landscape Index (SALI) analysis aided in identifying the activity cliffs in the dataset. The findings from the interaction analysis and SALI offer a comprehensive understanding of the Structure-Activity relationship of celecoxib analogues and deliver valuable insights for further lead optimization."

Journal • Inflammation

A randomised pilot trial of perioperative propranolol combined with celecoxib versus standard of care in stage III melanoma: The ProCel study protocol. (PubMed, PLoS One) - P2 | "In cutaneous melanoma patients, the presence of lymph node or in transit metastasis can be associated with poor survival. The trial is supported by Sydney Cancer Partners with funding from Cancer Institute NSW (Grant ID 2021/CBG0002). The sponsors are Sydney Local Health District and Melanoma Institute Australia."

Clinical protocol • IO biomarker • Journal • Cutaneous Melanoma • Melanoma • Oncology • Solid Tumor

Effects of celecoxib combined with duloxetine on chronic pain, depression, and anxiety in patients with knee osteoarthritis. (PubMed, World J Psychiatry) - "In patients with KOA, celecoxib plus duloxetine effectively mitigates chronic pain and improves anxiety and depressive symptoms without increasing adverse hepatic or renal effects. These findings support its use as a safe and effective treatment option."

Journal • CNS Disorders • Depression • Immunology • Mood Disorders • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Osteoarthritis • Pain • Psychiatry • Rheumatology